SLC5A2 and diabetes mellitus: In addition to diabetes management, SGLT2 inhibitors have shown promise in the areas of chronic kidney disease (CKD), and are able to reduce uric acid levels, attenuate oxidative stress, exert anti-inflammatory actions, improve fibrosis, decrease blood pressure, decrease body weight, and mitigate hyperlipidemia, cardiovascular disease, and even some cancers, such as early-stage lung adenocarcinoma (17) and pancreatic and prostate cancer cells (18), which are saturated with SGLT2 receptors.